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Dysregulation of Iron Metabolism 
in Cholangiocarcinoma Stem-like 
Cells
Chiara Raggi  1,2, Elena Gammella3, Margherita Correnti1, Paolo Buratti3, Elisa Forti1, Jesper 
B Andersen4, Gianfranco Alpini5, Shannon Glaser5, Domenico Alvaro6, Pietro Invernizzi7, 
Gaetano Cairo  3 & Stefania Recalcati3
Cholangiocarcinoma (CCA) is a devastating liver tumour arising from malignant transformation of 
bile duct epithelial cells. Cancer stem cells (CSC) are a subset of tumour cells endowed with stem-like 
properties, which play a role in tumour initiation, recurrence and metastasis. In appropriate conditions, 
CSC form 3D spheres (SPH), which retain stem-like tumour-initiating features. Here, we found different 
expression of iron proteins indicating increased iron content, oxidative stress and higher expression 
of CSC markers in CCA-SPH compared to tumour cells growing as monolayers. Exposure to the iron 
chelator desferrioxamine decreased SPH forming efficiency and the expression of CSC markers and 
stem-like genes, whereas iron had an opposite effect. Microarray profiles in CCA samples (n = 104) 
showed decreased H ferritin, hepcidin and ferroportin expression in tumours respect to surrounding 
liver, whereas transferrin receptor was up-regulated. Moreover, we found a trend toward poorer 
outcome in CCA patients with elevated expression of ferritin and hepcidin, two major proteins of 
iron metabolism. These findings, which represent the first evidence of a role for iron in the stem cell 
compartment as a novel metabolic factor involved in CCA growth, may have implications for a better 
therapeutic approach.
Cholangiocarcinoma (CCA), a rare and devastating adenocarcinoma arising from malignant transformation 
of bile duct epithelial cells, is the second most common form of primary liver tumour with increasing global 
incidence and mortality rates1. CCA severity and the limited benefit of the current therapeutic strategies have 
rendered this disease a major clinical challenge1,2. Therefore, understanding the cellular mechanisms underlying 
CCA cell growth is essential to develop novel chemopreventive and chemotherapeutic strategies.
Novel insights into the process of tumour evolution have been provided by the discovery of cancer stem cells 
(CSC) in many human solid tumours, including hepatic cancers (reviewed in3). CSC are a subset of cells within 
a tumour endowed with stem-like properties and higher resistance to chemotherapy compared to bulk tumour 
cells, which are involved in tumour initiation, recurrence and metastasis. CSC can be defined functionally by 
their extensive capacity to self-renew, express stem cell markers, differentiate into multiple lineages3. Moreover, 
CSC cultured in appropriate conditions resist to anoikis and tend to form 3D tumour spheres (SPH)4,5. Although 
the role of CSC in CCA is still obscure, we have recently highlighted the presence of a stem-like compartment in 
human liver cancer, including intrahepatic CCA, by using the functional tool of SPH formation4,6.
CSC tolerate the stressful conditions present in tumours, such as hypoxia, low pH, oxidative stress, inflam-
mation7–9; therefore, the involvement of iron in all of these settings10 strongly suggests that disruption of iron 
homeostasis may play an important role in CSC tumorigenicity and therapeutic resistance.
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Figure 1. Differential expression of proteins of iron metabolism in CCA cells. The CCA4, CCLP1 and 
HUCCT1 human CCA-derived cell lines were cultured as adherent monolayers (MON) or in 3D sphere 
conditions (SPH). Panel a. Top left, representative immunoblot analysis. Cell extracts were reacted with 
antibodies against transferrin receptor (TfR1), ferroportin (FPN), ferritin H subunit (FtH) and vinculin. 
Cropped blots are displayed. The original full blot images can be found in Supplementary Information. The 
graphs show densitometric quantification of immunoblot analyses. The values were normalized to vinculin 
and expressed as a fraction of respective MON cells normalized to 1. Mean values ± SEM (n = 6), *p ≤ 0.05, 
**p ≤ 0.01 vs control MON for each cell line. Panel b. RNA bandshift analysis of IRP activity. Cytoplasmic 
extracts were incubated with a 32P-labeled iron-responsive element (IRE) probe and RNA-protein complexes 
separated on non-denaturing polyacrylamide gels. On the left a representative autoradiogram is shown. A 
cropped gel is displayed. The original full gel image can be found in Supplementary Information. The graph 
on the right shows the densitometric quantification of IRPs bands by direct nuclear counting, as described in 
Materials and Methods; mean percentages ± SEM of control values (n = 6),, **p ≤ 0.01, ***p< 0.001 vs control 
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Iron can contribute to both tumour initiation and progression11,12. Excess iron can lead to reactive oxygen 
species (ROS) formation and mutagenesis, as shown by increased cancer in patients with iron overload, including 
liver cancer13. Moreover, due to their generally elevated proliferative potential, cancer cells have a greater meta-
bolic demand for iron than normal cells and hence express high levels of transferrin receptor (TfR1) to internalize 
transferrin-bound circulating iron. Indeed, iron chelators exert inhibitory effects on cell growth and have been 
considered for tumour therapy11,12. Over the last years, several studies have shown that reprogramming of iron 
metabolism is a key function for a tumour cell. In fact, it has been shown that downregulation of both the iron 
storage protein ferritin and the iron exporter ferroportin (FPN), together with increased TfR1 expression, leads 
to higher iron availability in a variety of cancer cells resulting in faster cell growth, and adverse prognosis in can-
cer patients14–17. In this study, taking advantage of a recently established and characterized 3D culture model of 
human CCA-SPH retaining stem-like tumour-initiating features4, we evaluated for the first time the role of iron 
in CCA, particularly focusing on the stem-compartment.
Results
CCA stem like cells have a profile of iron retention. We analyzed the expression of the major iron-re-
lated proteins in three distinct human intrahepatic CCA cell lines (CCA4, CCLP1 and HUCCT1)6 cultured both 
as adherent monolayers (MON) and in 3D SPH conditions, a culture system recently characterized and vali-
dated as a representation of CCA stem-like cells6. TfR1 protein levels in SPH were decreased to 10–20% of the 
value observed in MON (Fig. 1a). Conversely, the amount of ferritin H subunit was much higher in SPH than in 
attached cells, in line with the inverse correlation between the levels of ferritin and TfR110. These changes, which 
were mirrored in the levels of TfR1 mRNA (Fig. 1c), indicated that the SPH were iron rich, as confirmed by the 
lower binding activity of iron regulatory proteins (IRP), which regulate the expression of proteins of intracellular 
iron metabolism at the post-transcriptional level according to the labile iron pool (LIP)18 (Fig. 1b). H ferritin con-
tent appears to be controlled by IRP-mediated translational regulation, as we did not find significant differences 
in H ferritin mRNA levels between SPH and MON. Moreover, the expression of nuclear receptor coactivator 4 
(NCOA4), a protein that targets ferritin to autophagic degradation19, was the same in MON and SPH (results not 
shown). Conversely, IRP activity cannot account for the significant decrease of FPN levels in the SPH (Fig. 1a), as 
FPN translation is repressed when IRP activity is high18. The down-regulation of FPN, which is also transcription-
ally regulated20, may be the result of the decrease in FPN mRNA in SPH relative to MON (Fig. 1c). These modifi-
cations of cellular iron metabolism seem to be related to the switch from MON to SPH rather than to malignant 
transformation per se, as in general iron proteins in normal immortalized cholangiocytes (H69 cell line) were not 
significantly different than in CCA MON, with the exception of FPN, which was less expressed in tumour cells, in 
line with previous results in other tumours11 (Supplementary Fig. 1). Altogether, these findings indicate that the 
iron content is higher in SPH than in MON.
Iron dependency of SPH formation. To study the functional consequence of this altered expression of 
iron-related proteins, we evaluated whether changing cellular iron availability by exposure to iron or to an iron 
chelator may affect sphere-forming efficiency (SFE), as representation of tumour stem compartment6. We focused 
on CCLP1 and CCA4 cell lines, which were treated with ferric ammonium citrate (FAC) or the iron chelator des-
ferrioxamine (DFO) either as MON or SPH according to the experimental design illustrated in Fig. 2a. Treatment 
with FAC increased SFE significantly only in CCA4 cells, whereas iron chelation showed a greater effect in both 
cell lines, as the exposure to DFO reduced strongly the SFE in both CCLP1 and CCA4 cells (Fig. 2a). The involve-
ment of iron in SFE was supported by data showing TfR1 expression analyzed in parallel under the same condi-
tions (Fig. 2b). In fact, the analysis of TfR1 at both the mRNA and protein levels, as indicator of intracellular iron 
levels, showed that the effect of DFO was stronger in SPH, possibly because of their higher basal iron content. 
Overall, these results indicated that SPH have increased iron dependence.
Increased ROS production in SPH. The differences in iron levels were accompanied by changes in oxi-
dative stress: both the expression of heme oxygenase (HO-1), a well-known marker of oxidative stress, and ROS 
levels, were induced by FAC and decreased by DFO. Notably, under basal conditions, oxidative stress was remark-
ably higher in untreated SPH than in MON (Fig. 3a). To further address the pathogenetic role of the different iron 
availability, we evaluated cell growth in MON and SPH after manipulation of iron content by FAC or DFO; the 
number of viable cells was increased by iron supplementation and decreased by chelation in MON, as expected 
on the basis of previous studies21, and also in SPH (Supplementary Fig. S2).
Since excess iron might render SPH more susceptible to ferroptosis, a recently characterized mechanism 
which causes regulated cell death through iron-dependent ROS production and lipid peroxidation22, we treated 
CCLP1 and CCA4 cells with erastin, a ferroptosis inducing agent. Exposure to increasing concentrations of eras-
tin progressively decreased cell viability, but SPH were remarkably more resistant than MON at concentrations 
above 0.5 µM (Fig. 3b).
Effect of iron on the expression of stem like genes. Next, in order to explore the effects of cellular iron 
levels in the modulation of stem-like genes, we performed a molecular characterization by qRT-PCR of both CCA 
SPH and MON exposed to DFO or FAC. Overall, MON were more susceptible to FAC treatment (46.2% of genes 
MON for each cell line. Panel c. TfR1 and FPN mRNA levels were measured by quantitative RT-PCR. Samples 
were analyzed in triplicate, normalized to the housekeeping gene 18 S and expressed as percentage of respective 
MON cells normalized to 1. Mean values ± SEM (n = 6), **p ≤ 0.01 vs control MON for each cell line.
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regulated in CCA4 and 84% in CCLP1) than to DFO (26.9% of genes regulated in CCA4 and 8% in CCLP1), 
whereas gene expression in the SPH was more affected by iron chelation (84% of genes regulated in CCA4 and 
50% in CCLP1 after exposure to DFO) than by iron supplementation (8% of genes regulated in CCA4 and 12.5% 
Figure 2. Effect of different iron availability on self-renewal capacity in vitro. Panel a. Top: schematic 
overview of the treatment protocols. Bottom: sphere-forming efficiency (SFE) of CCLP1 and CCA4 MON or 
SPH untreated (CTRL), treated with ferric ammonium citrate (FAC) (100 µg/ml) or desferioxamine (DFO) 
(100 µM). Mean ± SEM (n = 3), *p ≤ 0.01, ***p ≤ 0.001 vs CTRL MON (left) or vs CTRL SPH (right) for each 
cell line. Panel b. TfR1 expression in CCLP1 and CCA4 cell lines cultured and treated as described above. Left: 
cell extracts were reacted with antibodies against transferrin receptor (TfR1) and vinculin. A representative 
immunoblot analysis and the densitometric quantification are shown. The values were normalized to vinculin 
and expressed as a fraction of respective MON cells normalized to 1. Mean values ± SEM (n = 6), *p ≤ 0.01, 
**p ≤ 0.01 vs CTRL MONO for each cell line; ##p ≤ 0.01 vs CTRL SPH. Right: TfR1 mRNA levels were 
measured by quantitative RT-PCR as described in the legend to Fig. 1. Mean values ± SD (n = 3), *p ≤ 0.05, 
**p ≤ 0.01 vs CTRL MONO for each cell line.; ##p ≤ 0.01 vs CTRL SPH.
www.nature.com/scientificreports/
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in CCLP1). Among a panel of 32 stem-like genes specifically involved in pluripotency and self-renewal, epithe-
lial mesenchymal transition (EMT) and survival, in addition to well-known CSC-related markers, we identified 
commonly up-regulated genes for both CCA cell lines exposed to iron as MON. In fact, enhanced expression 
of CD133, epithelial cell adhesion molecule (EpCAM), cMYC, octamer binding transcription factor 4 (OCT4), 
Kruppel-like factor 4 (KLF4), fibroblast growth factor (FGF), β-catenin, Zinc finger, E-box-binding homeobox 1 
(ZEB1) and human Snail family transcriptional repressor (SLUG or SNAI2) genes was found in both CCA4 and 
CCLP1 MON treated with FAC (Fig. 4a). Similarly, CCA4 and CCLP1 SPH exposed to DFO showed common 
reduced expression of CD133, EpCAM, tyrosine-protein kinase Kit (cKIT), SRY (sex determining region Y)-box 
2 (SOX2), Notch homolog 1 (NOTCH1), Twist-related protein 1 (Twist) and epithelial cadherin (E-cadherin) 
(Fig. 4b), thus suggesting a clear involvement of iron metabolism in the modulation of tumour stem-like features 
of CCA.
Expression of iron related genes in human CCA. To assess whether iron metabolism is altered in CCA, 
we analyzed the transcriptome of 104 CCA patients23. First, we compared gene expression in tumour (T) tissue 
and matched surrounding liver (SL). H ferritin and FPN mRNA levels in T were significantly reduced compared 
to SL, whereas TfR1 mRNA levels were up-regulated (Fig. 5a), a result in line with the typical “iron seeking” phe-
notype previously described in other tumours11. We also analyzed hepcidin (HAMP), a liver-derived hormone 
that controls body iron balance by binding to FPN and inducing its internalization and degradation, thereby 
Figure 3. Redox status and ferroptosis in CCA cells growing as monolayers or spheres. Panel a. CCLP1 
and CCA4 cells cultured both as MON and SPH were left untreated (CTRL), treated with ferric ammonium 
citrate (FAC) (100 µg/ml) or desferioxamine (DFO) (100 µM). Left: HO-1 mRNA levels were measured by 
quantitative RT-PCR as described in the legend to Fig. 1. Mean values ± SEM (n = 3), *p ≤ 0.05, ***p ≤ 0.001 
vs CTRL MON, ##p ≤ 0.01 vs CTRL SPH. Right: ROS production was evaluated by means of the DCFDA assay 
as described in Materials and Methods. Samples were analyzed in triplicate, normalized to protein content and 
expressed as percentage of untreated cells normalized to 1. Mean values ± SEM (n = 3), *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001 vs CTRL MON; ###p ≤ 0.001 vs CTRL SPH. Panel b. MON and SPH were treated for 18 h with 
increasing concentrations of the ferroptosis inducer erastin and cell viability was evaluated by means of the 
MTT reduction assay. Mean values ± SEM (n = 5), *p ≤ 0.05, ***p ≤ 0.001 vs MON for each point.
www.nature.com/scientificreports/
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blocking iron efflux24. HAMP expression was significantly decreased in T compared to SL (Fig. 5b), a result 
apparently in contrast with the low FPN expression. This strong difference in HAMP expression prompted us to 
evaluate HAMP expression in CCA cell lines. Compared to the hepatocarcinoma cell line HepG2, HAMP tran-
script levels were greatly reduced in normal immortalized cholangiocytes (H69 cell line) and decreased further in 
CCA cell lines (Supplementary Fig. 3), thus explaining the decreased HAMP expression in T. Moreover, HAMP 
expression did not change significantly between MON and SPH.
Prognostic relevance of perturbations in iron metabolism in CCA. Next, to study the relationship 
between iron metabolism and prognosis in CCA, the 104 CCA patients were divided into 2 groups based on their 
median gene expression level of iron proteins. Correlation analysis with overall survival (OS) showed a trend 
toward poor prognosis in patients with higher HAMP expression (p = 0.059) (Fig. 5b); analysis of other iron 
related genes did not show statistical significance. These findings were supported by data obtained analysing The 
Cancer Genome Atlas (TCGA) database of 38 CCA tumours25 in which Kaplan Mayer curves showed that both 
OS and disease free survival (DFS) were significantly shorter in patients with HAMP gene alterations (amplifica-
tion or mRNA upregulation) than in subjects without alterations (Supplementary Fig. 4).
Given the high content of stromal cells typically observed in CCA, we then analyzed 23 CCA, randomly 
selected from the 104 cohort, by laser capture microdissection of the tumour into epithelial (EPI) and stromal 
cell (S) compartments23. Patients with high H ferritin expression in the EPI tumour compartment showed a trend 
toward shorter OS compared to patients with low H ferritin expression (Fig. 5c). No differences were found in 
the S compartment.
Taken together these results indicate that patients with higher iron accumulation in tumour cells showed a 
worse prognosis.
Figure 4. Effect of different iron availability on the expression of stemness-associated genes in monolayers and 
spheres. CCLP1 and CCA4 cells growing as monolayers (MON) or spheres (SPH) were left untreated (CTRL), 
treated for 18 h with ferric ammonium citrate (FAC) (100 µg/ml) or with desferioxamine (DFO) (100 µM). The 
expression of the indicated genes was measured by quantitative RT-PCR as described in the legend to Fig. 1. 
Panel a. Commonly up-regulated genes in FAC-treated MON. Panel b. Commonly down-regulated genes in 
DFO-treated SPH. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 vs CTRL MON (panel a) or SPH (panel b) for each cell 
line.
www.nature.com/scientificreports/
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Discussion
The major finding of this study relates to the mechanisms and consequences of increased iron retention in CCA 
CSC as a novel metabolic factor involved in CCA growth. We showed that the expression of the major proteins of 
intracellular iron trafficking is opposite between MON, which have a pattern indicative of low iron content, and 
SPH, which have a phenotype symptomatic of elevated intracellular iron availability.
Recent evidence showed that the regulation of iron homeostasis is altered in cancer14–17; tumour cells generally 
require more iron than their normal counterparts for a number of functions mainly linked to cell proliferation21. 
Accordingly, most cancer cells show increased expression of TfR1 and reduced levels of FPN, which jointly lead 
to high intracellular iron availability. Therefore, according to the well-known inverse correlation between ferritin 
Figure 5. Analysis of correlation between the expression of genes of iron metabolism and CCA patients 
survival in two different data sets. Panel a. Expression of Ft H subunit (FTH), ferroportin (FPN) and transferrin 
receptor (TfR1) in CCA tumour samples (T) and healthy liver tissue (SL) in CCA patients. Panel b. Left: 
expression of hepcidin (HAMP) in CCA tumour samples (T) and healthy liver tissue (SL). Right: correlation 
between hepcidin expression and survival in a database of 104 CCA patients. Analysis was performed using 
a Cox proportional hazards model. Overall survival (OS) was demonstrated by Kaplan–Meier and log-rank 
statistics. Panel c. Left: Ft H subunit gene expression level in intratumoural epithelial (EPI) cells. Right: 
correlation between Ft H subunit gene expression in the EPI compartment and disease outcome. The epithelial 
tumour compartment was isolated by laser micro-dissection in a set of CCA patients (n = 23).
www.nature.com/scientificreports/
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and TfR110, one should expect low ferritin content in tumours, as found in breast cancer cells11. However, ferritin 
upregulation has been reported in several cancer tissues11. These apparent discrepancies are possibly explained 
by increased ferritin expression in stromal26 and inflammatory cells27 within the tumour. Conversely, the role 
of ferritin repression in increasing iron availability for the high requirements of tumor cells themselves is sup-
ported by studies showing that oncogenes like Myc in B cells28, adenovirus E1A29 and Ras30 downregulate ferritin 
expression. Inactivation of tumour suppressors may exert a similar effect, as loss of adenomatous polyposis coli 
(APC) was accompanied by decreased ferritin content in colon cancer31, whereas wild type p53 decreases IRP 
activity32 by affecting iron availability33 and impairing iron-sulfur cluster assembly34, thereby inducing ferritin. 
In this study, we found a typical pattern (H ferritin low-TfR1 high), indicative of low iron levels, in CCA MON 
and when we compared tumour tissue with the surrounding healthy liver in CCA patients (Fig. 5a). Conversely, 
a completely different picture emerged in the SPH, which are representative of CSC, and were characterized by 
elevated iron content (Fig. 1). Our data strongly suggest that the increased iron level in SPH may result from the 
low expression of FPN mRNA, which leads to a decrease in FPN levels despite the absence of IRP-mediated trans-
lational repression (Fig. 1). Indeed, downregulation of FPN is typical of cancer cells15,17, although its role in CSC 
has not been previously investigated. However, we presently cannot rule out that iron accumulation may be just 
the consequence of a slower rate of cell division or diminished metabolic consumption.
Notably, the high expression of H ferritin found in SPH is in keeping with the results obtained when we 
analyzed gene expression selectively in CCA epithelial cells (Fig. 5c), an approach that allowed us to minimize a 
possible confounding problem related to the great presence of stromal cells in CCA3. Although not statistically 
significant, probably because of relatively small sample number, we found a trend toward shorter survival in 
patients with higher H ferritin levels, thus suggesting a role for CSC in the CCA of these patients. A similar result 
was found in glioblastoma stem-like cells35 and our findings are also in line with the CSC induction observed in 
human lung cancer cells exposed to iron36. Conversely, a recent study showed that low H ferritin expression is 
correlated to efficient CCS formation and shorter survival in ovarian cancer16. This discrepancy may be related to 
the several differences existing between distinct types of tumors.
We also found a strong decrease in hepcidin expression in CCA samples as compared to SL, a result in line 
with the elevated serum hepcidin found in many tumors11. Although some cancer cells produce hepcidin11, in the 
case of CCA, hepcidin is probably produced by hepatocytes, as suggested by cell specific differences in hepcidin 
expression between hepatocytes and cholangiocytes (see Supplementary Fig. 3). However, the shorter survival of 
patients with high hepcidin expression is in keeping with the inhibitory effect of hepcidin on cellular iron release.
Altogether, these data suggest that the increased iron content in CSC may be a key feature associated with the 
progression of CCA (Fig. 6).
Whether the increased iron content leads to CSC formation or is a consequence of stemness remains to be 
determined. In support of the first hypothesis, we found decreased SPH formation in the presence of an iron che-
lator (Fig. 3), in line with results obtained in lung cancer cells36 and medulloblastoma37, thus suggesting that the 
higher amount of iron may have a functional role. In addition, differential gene expression analysis showed that 
genes involved in stemness and EMT are induced by iron supplementation and down-modulated by iron chela-
tion. In particular, iron modulated the Wnt-β-catenin pathway, as shown by induction of β-catenin and its down-
stream targets MYC and EpCAM in iron-treated MON and repression in SPH exposed to DFO (Fig. 4). The iron 
dependence of β-catenin signaling in CCA shown here is in line with the demonstration that several compounds 
Figure 6. Iron homeostasis is altered in human CCA-CSC and CCA patients. CCA SPH expressing CSC 
markers are characterized by different expression of iron proteins indicating high iron content and oxidative 
stress. Likewise, a trend toward poorer outcome was found in CCA patients with high expression of Ft H and 
hepcidin in cancer cells.
www.nature.com/scientificreports/
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with different structures, but having iron chelating capacity in common, are able to inhibit various types of can-
cer, such as multiple myeloma38 and colorectal cancer31,39–41 by targeting β-catenin signalling. This mechanism 
may be pathogenetically significant, as increased β-catenin levels have been observed in a high percentage of 
CCA (reviewed in42). Furthermore, EMT-inducing transcription factors, such as SLUG and TWIST, which are 
associated with invasion, poor differentiation and short survival42, are also regulated by iron availability (Fig. 5). 
Moreover, our finding that TfR1 is markedly repressed in SPH, which show high expression of EMT markers 
relative to MON (Fig. 5), is consistent with the impaired EMT progression found in tumor cells treated with iron 
chelators, which induce TfR143, and with the recent demonstration that TfR1 inhibits EMT in intestinal epithelial 
cells44. Conversely, glioblastoma stem-like cells, which critically require high levels of ferritin, also showed high 
expression of TfR135, although the molecular mechanism allowing elevated synthesis of both proteins is not in 
line with the current model of regulation of intracellular iron homeostasis10. In agreement with the connection 
between elevated iron in the LIP and oxidative stress10,18, we found increased ROS levels and induction of HO-1 
in SPH compared to MON and we also showed an association between SFE and ROS (Figs 2 and 4). It is well 
accepted that cancer cells generate more ROS than their normal counterparts, whereas the microenvironment 
of normal stem cells is characterized by low levels of ROS45. On the other hand, much less is known about the 
biological effects of ROS in CSC, although some studies showed that CSC produce less ROS than other tumour 
cells and CSC expressing the common marker CD44, which facilitates glutathione synthesis, are more resistant 
to oxidative stress46. We can speculate that elevated ferritin synthesis in CCA SPH is not sufficient to store iron 
and excessive free iron promotes the formation of radical species. In keeping with the present findings, a similar 
ROS-mediated induction of CSC was recently found in iron-treated lung cancer cells36. The higher levels of iron 
and ROS in SPH prompted us to investigate whether they were more susceptible to ferroptosis. However, we 
unexpectedly found that SPH were less vulnerable to ferroptosis, perhaps in relation to their resistance to various 
types of chemoterapeutic agents3.
An alternative hypothesis is that genes associated to CSC may modify iron homeostasis. Since the membrane 
protein CD133 is a negative regulator of Tf endocytosis, and hence of TfR1-mediated iron uptake47, the changes 
in CD133 expression found in MON and SPH, which are opposite to those of TfR1, may affect CSC iron status 
and lead to high LIP. Obviously, it is also well plausible that the two possibilities are not mutually exclusive but 
progressively interact, ultimately disrupting iron homeostasis in CCA. For example, MYC, which plays a key role 
in liver CSC development and maintenance48 and is modulated by cellular iron content (Fig. 4), has been shown 
to inhibit ferritin expression in tumour cells28,31.
The current model of altered iron homeostasis in cancer cells can be summarized in a framework in which 
increased iron uptake and decreased iron storage and export contribute to enhancing the levels of iron to sustain 
the high requirement of growing tumour cells. We confirmed this “iron regulatory gene signature”49 in MON, 
but a different picture emerged from the analysis of iron metabolism in CCA SPH, an accepted model of CSC, as 
our findings revealed elevated iron storage and oxidative stress. This increased iron dependency is accompanied 
by substantial changes in the expression of CSC markers that can be reversed by iron removal and is mirrored by 
data indicating a trend toward shorter survival in CCA patients with elevated hepcidin expression and higher H 
ferritin expression in epithelial cells, indicative of high iron retention (Fig. 6).
By giving insights into the particular regulation of iron homeostasis in the stem compartment of CCA, this 
study provides advances in the understanding of the pathogenesis of this deadly tumour that may hopefully trans-
late into an effective adjunct therapeutic approach based on iron deprivation.
Methods
Cell culture and treatments. The human intrahepatic CCA cell lines CCLP1, HUCCT1 (a kind gift from 
A.J. Demetris, Pittsburgh) and CCA4 were previously described6. The human immortalized non-malignant chol-
angiocyte cell line H69 was kindly provided by Dr. G. J. Gores (Mayo Clinic, Rochester). The cell lines were 
grown at 37 °C in a humidified incubator at 5% CO2 as monolayers (MON) in DMEM medium or spheres (SPH) 
in anchoring-independent conditions with selective serum-free DMEM/F12 medium supplemented with 1X 
B27 supplement minus vitamin A (Life Technologies, Monza, Italy), human recombinant EGF (R&D System, 
Milano, Italy) (20 ng/mL) and bFGF (R&D System) (20 ng/mL)4,6. Cells were treated for 18 hours with 100 µM 
Desferioxamine (DFO) (Sigma Aldrich, Milano, Italy) or 100 µg/ml ferric ammonium citrate (FAC) (Sigma 
Aldrich) or increasing concentrations of erastin (Sigma Aldrich).
Sphere assay. The cells were grown in anchoring-independent conditions (see above4,6). After 15 days, the 
SPH were counted, and the SFE was calculated by dividing the number of SPH by the original number of single 
cells seeded and expressed as a percentage. SPH morphology was assessed using an Olympus IX81 confocal 
microscope as previously reported4. Large-scale SPH cultures were established by plating 1.8 × 103 cells/cm2 into 
poly (2-hydroxyethyl methacrylate) (poly-HEMA, Sigma Aldrich) coated dishes in the presence of 1% methyl-
cellulose (R&D System).
Quantitative real-time polymerase chain reaction. Total RNA isolated from SPH or MON using TRI 
reagent® (Sigma Aldrich) was reverse transcribed into cDNA with Proto Script M-MuLV First Strand cDNA 
Synthesis Kit (New England Biolabs, Pero, Italy) and the obtained cDNA served as a template for Real-Time 
PCR. Changes in the mRNA levels were detected by amplification of each sample in triplicate using FAST 
SYBR-Green PCR Master Mix and the 7900HT Fast Real Time PCR System (Applied Biosystems, Monza, 
Italy) and gene-specific primer pairs (see Table 1) or by real time PCR based on the TaqMan methodology (Life 
Technologies) using the primers indicated in Table 2 (Applied Biosystems). The levels of 18 S RNA were used 
for normalization. For all tested genes, the fold difference (2−∆∆Ct) was calculated using the ∆Ct of respective 
untreated sample as a control. All reactions were performed in triplicate.
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Immunoblotting analysis. Proteins in cell extracts were separated by electrophoresis and transferred to 
nitrocellulose. Filters were incubated for 1 hour at room temperature with the primary antibodies indicated in 
Table 3 and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (Cell 
Signaling or BioRad, Milano, Italy). The signals were revealed using the ECL method (Amersham, Pero, Italy) 
and quantified using ImageLab 5.2.1 software with the values being calculated after normalisation to the amount 
of vinculin.
RNA-protein bandshift assay. Equal amounts of proteins from cell lysates prepared as previously 
described50 were incubated with a molar excess of IRE probe transcribed in vitro from the pSPT-fer plasmid con-
taining the IRE of the human ferritin H chain in the presence of 100 µCi of (α-32P) UTP (800 Ci/mmol) (Perkin 
Elmer, Milano, Italy) and sequentially treated with RNase T1 and heparin as previously described50. After separa-
tion on non-denaturing polyacrylamide gels, the IRPs-RNA complexes were visualized autoradiographically and 
quantified by means of direct nuclear counting using an InstantImager (Packard Instruments, Meriden CT, USA).
Reactive oxygen species detection. ROS production was monitored using the dichloro-dihydro-fluorescein 
diacetate (DCFH-DA) fluorescent probe (Sigma Aldrich), a cell-permeable indicator of ROS. Cells cultured as MON 
or SPH as described above were stained by re-suspending in 20 µM DCFH-DA and incubated at 37 °C for 30 minutes 
in the dark. Fluorescence was measured (nm: 495 excitation and 529 emission).
MTT assay. Cells grown as MON or SPH were left untreated or treated with FAC or DFO. At the end of the 
treatments, cell viability was measured using thiazolyl blue (MTT, Sigma Aldrich, Milano, Italy) as an indicator 
of mitochondrial function. After incubation with the MTT solution (5 mg/ml) at 37 °C for 2 hours, formazan 
crystals were dissolved by adding the MTT solubilization solution. Absorbance was read at 570 nm, and the back-
ground absorbance at 690 nm was subtracted.
Gene Primer Forward Primer Reverse
CD133 GCTTCAGGAGTTTCATGTTGG GGGGAATGCCTACATCTGG
EpCAM TGTGGTGATAGCAGTTGTTGC CTATGCATCTCACCCATCTCC
cKIT TTGGGGTTGTGTTGTCACC TGAAGTGCCCCTGAAGTACC
cMYC CGGAACTCTTGTGCGTAAGG ACTCAGCCAAGGTTGTGAGG
OCT4 TTGTGCCAGGGTTTTTGG ACTTCACCTTCCCTCCAACC
KLF4 AGACAGTCTGTTATGCACTGTGG TGTTCTGCTTAAGGCATACTTGG
SOX2 ATGGGTTCGGTGGTCAAGT GGAGGAAGAGGTAACCACAGG
bFGF GGCTATGAAGGAAGATGGAAGATT GGCTATGAAGGAAGATGGAAGATT
NOTCH1 GCAGTTGTGCTCCTGAAGAA CGGGCGGCCAGAAAC
Bcat GCTGGGACCTTGCATAACCTT ATTTTCACCAGGGCAGGAATG
TWIST GGAGTCCGCAGTCTTACGAG TCTGGAGGACCTGGTAGAGG
Ecad AGGCCAAGCAGCAGTACATT ATTCACATCCAGCACATCCA
ZEB1 AAGAAAGTGTTACAGATGCAGCTG CCCTGGTAACACTGTCTGGTC
SLUG GGGGAGAAGCCTTTTTCTTG TCCTCATGTTTGTGCAGGAG
Rn18s CCACTTTCGATGGTAGTCG CCTTCCTTGGATGTGGTA
Table 1. Primers for SYBR-Green PCR.
Gene Primer
TfR1 Ms00951083-m1
Fpn Ms00205888-m1
Rn18s Hs03928985-g1
HO-1 Ms01110250-m1
HAMP Hs00221783-m1
Table 2. Primers for TaqMan PCR.
Protein name Antibody Incubation
Fpn Novus Biologicals NBP1-21502 1:1500
FtH anti-H Ft subunit monoclonal antibody (see ref.50) 1:1000
TfR1 Invitrogen 136800 1:500
Vinculin Cell Signalling #4650 1:5000
Table 3. Antibodies.
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Statistical analysis. Results are expressed as mean ± SEM, as specified. Statistical significance between 
groups was assessed by Student’s t test with Prism software (version 6.00 for Windows; GraphPad).
CCA patient data base and statistical analysish. The GSE26566 series matrix containing gene 
expression values from Illumina humanRef-8 v2.0 bead chips of 104 CCA (T) and 59 matched noncancerous 
surrounding liver (SL) samples was downloaded from GEO23. 23 random CCA cases were selected for laser 
microdissection of both the tumour epithelial and stromal component. Differences in gene expression of selected 
genes were evaluated and data represented as box plots with 5–95 percentiles (GraphPad Prism v5). Genes of iron 
metabolism were also evaluated using The Cancer Genome Atlas (TCGA) database of 38 CCA tumours in which 
DNA mutations, RNA expression, copy number and DNA methylation were assessed25. Statistical significance 
was calculated using Mann Whitney test (2-tailed). Overall survival was calculated based on the median gene 
expression and shown as Kaplan-Meier plots with log Rank statistics. Pearson correlation between gene pairs was 
calculated using R and the “cortest” function, yielding correlation coefficients and p-values.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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